Analysis of TSC Cortical Tubers by Deep Sequencing of TSC1, TSC2 and KRAS Demonstrates that Small Second-Hit Mutations in these Genes are Rare Events

Translational Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Brain Pathology (Impact Factor: 3.84). 11/2010; 20(6):1096-105. DOI: 10.1111/j.1750-3639.2010.00416.x
Source: PubMed


Tuberous sclerosis complex (TSC) is an often severe neurocutaneous syndrome. Cortical tubers are the predominant neuropathological finding in TSC, and their number and location has been shown to correlate roughly with the severity of neurologic features in TSC. Past studies have shown that genomic deletion events in TSC1 or TSC2 are very rare in tubers, and suggested the potential involvement of the MAPK pathway in their pathogenesis. We used deep sequencing to assess all coding exons of TSC1 and TSC2, and the activating mutation hot spots within KRAS in 46 tubers from TSC patients. Germline heterozygous mutations were identified in 81% of tubers. The same secondary mutation in TSC2 was identified in six tuber samples from one individual. Further study showed that this second hit mutation was widely distributed in the cortex from one cerebral hemisphere of this individual at frequencies up to 10%. No other secondary mutations were found in the other 40 tubers analyzed. These data indicate that small second hit mutations in any of these three genes are very rare in TSC tubers. However, in one TSC individual, a second hit TSC2 point mutation occurred early during brain development, and likely contributed to tuber formation.

18 Reads
  • Source
    • "LOH has been convincingly demonstrated in most of the neoplasms associated with TSC including subependymal giant cell astrocytomas (SEGAs), angiomyolipomas, cardiac rhabdomyomas, and lymphangioleiomyomatosis (LAM). Biallelic inactivation has been detected, but in only a small number of cells within cortical tubers (Crino et al., 2010; Qin et al., 2010). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The mechanistic target of rapamycin (mTOR) signaling pathway is a crucial cellular signaling hub that, like the nervous system itself, integrates internal and external cues to elicit critical outputs including growth control, protein synthesis, gene expression, and metabolic balance. The importance of mTOR signaling to brain function is underscored by the myriad disorders in which mTOR pathway dysfunction is implicated, such as autism, epilepsy, and neurodegenerative disorders. Pharmacological manipulation of mTOR signaling holds therapeutic promise and has entered clinical trials for several disorders. Here, we review the functions of mTOR signaling in the normal and pathological brain, highlighting ongoing efforts to translate our understanding of cellular physiology into direct medical benefit for neurological disorders.
    Neuron 10/2014; 84(2):275-291. DOI:10.1016/j.neuron.2014.09.034 · 15.05 Impact Factor
  • Source
    • "This may be because biallelic mutation is necessary to induce severe morphological alteration such as tubers or giant astrocytomas. In fact, so-called “two-hit” mechanisms of germline mutation and somatic mutation have been proposed for human tubers of TSC patients (Crino et al., 2010), although another report argued that the second hit was rare (Qin et al., 2010). The two-hit mechanism has been evaluated with homozygous deletion of TSC2 only in radial glia, and heterozygous deletion in all other cells by crossing Tsc2+/-, Tsc2flox, and GFAP-Cre mice (Way et al., 2009). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Target of rapamycin (TOR) was first identified in yeast as a target molecule of rapamycin, an anti-fugal and immunosuppressant macrolide compound. In mammals, its orthologue is called mammalian TOR (mTOR). mTOR is a serine/threonine kinase that converges different extracellular stimuli, such as nutrients and growth factors, and diverges into several biochemical reactions, including translation, autophagy, transcription, and lipid synthesis among others. These biochemical reactions govern cell growth and cause cells to attain an anabolic state. Thus, the disruption of mTOR signaling is implicated in a wide array of diseases such as cancer, diabetes, and obesity. In the central nervous system, the mTOR signaling cascade is activated by nutrients, neurotrophic factors, and neurotransmitters that enhances protein (and possibly lipid) synthesis and suppresses autophagy. These processes contribute to normal neuronal growth by promoting their differentiation, neurite elongation and branching, and synaptic formation during development. Therefore, disruption of mTOR signaling may cause neuronal degeneration and abnormal neural development. While reduced mTOR signaling is associated with neurodegeneration, excess activation of mTOR signaling causes abnormal development of neurons and glia, leading to brain malformation. In this review, we first introduce the current state of molecular knowledge of mTOR complexes and signaling in general. We then describe mTOR activation in neurons, which leads to translational enhancement, and finally discuss the link between mTOR and normal/abnormal neuronal growth during development.
    Frontiers in Molecular Neuroscience 04/2014; 7(1):28. DOI:10.3389/fnmol.2014.00028 · 4.08 Impact Factor
  • Source
    • "Other neurodevelopmental disorders occasionally result from somatic mutations, including DCX (Gleeson et al., 2000) and NF1 (Messiaen et al., 2011; Vogt et al., 2011), but these have generally not been mutations limited to brain. In addition, some tubers from individuals with TSC, who carry germline mutations in TSC1 or TSC2, have been demonstrated to have somatic " second hits' in the TSC2 gene (Qin et al., 2010). We hypothesized that the somatic mutations causing HMG might be essentially restricted to the brain and detectable by direct study of affected brain tissue. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Hemimegalencephaly (HMG) is a developmental brain disorder characterized by an enlarged, malformed cerebral hemisphere, typically causing epilepsy that requires surgical resection. We studied resected HMG tissue to test whether the condition might reflect somatic mutations affecting genes critical to brain development. We found that two out of eight HMG samples showed trisomy of chromosome 1q, which encompasses many genes, including AKT3, a gene known to regulate brain size. A third case showed a known activating mutation in AKT3 (c.49G→A, creating p.E17K) that was not present in the patient's blood cells. Remarkably, the E17K mutation in AKT3 is exactly paralogous to E17K mutations in AKT1 and AKT2 recently discovered in somatic overgrowth syndromes. We show that AKT3 is the most abundant AKT paralog in the brain during neurogenesis and that phosphorylated AKT is abundant in cortical progenitor cells. Our data suggest that somatic mutations limited to the brain could represent an important cause of complex neurogenetic disease.
    Neuron 04/2012; 74(1):41-8. DOI:10.1016/j.neuron.2012.03.010 · 15.05 Impact Factor
Show more

Preview (2 Sources)

18 Reads
Available from